VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $23.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $23.70M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $40.70M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $48.60M, a 50.91% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $36.60M, a 480.95% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$143.70M, a 201.13% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $142.10M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$15.10M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$15.10M, a 117.89% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.70M 10-Q · filed 2026-08-04 | $64.40M 10-Q · filed 2026-08-04 | $113.00M derived: sum of 3 quarters · filed 2026-08-04 | $149.60M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $40.70M 10-Q · filed 2026-05-05 | $89.30M derived: sum of 2 quarters · filed 2026-05-05 | $125.90M derived: sum of 3 quarters · filed 2026-05-05 | -$43.30M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $48.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $85.20M derived: sum of 2 quarters · filed 2026-02-13 | -$84.00M derived: sum of 3 quarters · filed 2026-08-04 | -$143.70M 10-K · filed 2026-02-13 | |||
| 2025-09-30 | $36.60M 10-Q · filed 2025-11-04 | -$132.60M derived: sum of 2 quarters · filed 2026-08-04 | -$192.30M 10-Q · filed 2025-11-04 | -$93.30M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | -$169.20M 10-Q · filed 2026-08-04 | -$228.90M 10-Q · filed 2026-08-04 | -$129.90M derived: sum of 3 quarters · filed 2026-08-04 | -$123.60M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | -$59.70M 10-Q · filed 2026-05-05 | $39.30M derived: sum of 2 quarters · filed 2026-05-05 | $45.60M derived: sum of 3 quarters · filed 2026-05-05 | $50.80M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $99.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $105.30M derived: sum of 2 quarters · filed 2026-02-13 | $110.50M derived: sum of 3 quarters · filed 2026-02-13 | $142.10M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $6.30M 10-Q · filed 2025-11-04 | $11.50M derived: sum of 2 quarters · filed 2025-11-04 | $43.10M 10-Q · filed 2025-11-04 | $31.80M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-06-30 | $5.20M 10-Q · filed 2025-08-05 | $36.80M 10-Q · filed 2025-08-05 | $25.50M derived: sum of 3 quarters · filed 2026-02-13 | $62.30M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-03-31 | $31.60M 10-Q · filed 2025-05-06 | $20.30M derived: sum of 2 quarters · filed 2026-02-13 | $57.10M derived: sum of 3 quarters · filed 2026-02-13 | $30.40M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2023-12-31 | -$11.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $25.50M derived: sum of 2 quarters · filed 2026-02-13 | -$1.20M derived: sum of 3 quarters · filed 2026-02-13 | -$15.10M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $36.80M 10-Q · filed 2024-11-05 | $10.10M derived: sum of 2 quarters · filed 2024-11-05 | -$3.80M 10-Q · filed 2024-11-05 | -$100.60M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-06-30 | -$26.70M 10-Q · filed 2024-08-02 | -$40.60M 10-Q · filed 2024-08-02 | -$137.40M derived: sum of 3 quarters · filed 2025-02-13 | -$97.30M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-03-31 | -$13.90M 10-Q · filed 2024-05-07 | -$110.70M derived: sum of 2 quarters · filed 2025-02-13 | -$70.60M derived: sum of 3 quarters · filed 2025-02-13 | -$24.40M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2022-12-31 | -$96.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$56.70M derived: sum of 2 quarters · filed 2025-02-13 | -$10.50M derived: sum of 3 quarters · filed 2025-02-13 | -$15.10M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $40.10M 10-Q · filed 2023-11-07 | $86.30M derived: sum of 2 quarters · filed 2023-11-07 | $81.70M 10-Q · filed 2023-11-07 | $86.10M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $46.20M 10-Q · filed 2023-08-02 | $41.60M 10-Q · filed 2023-08-02 | $46.00M derived: sum of 3 quarters · filed 2024-02-15 | $82.70M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | -$4.60M 10-Q · filed 2023-05-02 | -$200.00K derived: sum of 2 quarters · filed 2024-02-15 | $36.50M derived: sum of 3 quarters · filed 2024-02-15 | $44.60M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2021-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $41.10M derived: sum of 2 quarters · filed 2024-02-15 | $49.20M derived: sum of 3 quarters · filed 2024-02-15 | $84.40M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $36.70M 10-Q · filed 2022-10-28 | $36.70M 10-Q · filed 2021-11-03 | $44.80M derived: sum of 2 quarters · filed 2022-10-28 | $80.00M 10-Q · filed 2022-10-28 | $80.02M 10-Q · filed 2021-11-03 | $52.51M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-06-30 | $8.10M 10-Q · filed 2022-08-05 | $8.14M 10-Q · filed 2021-07-30 | $43.30M 10-Q · filed 2022-08-05 | $43.32M 10-Q · filed 2021-07-30 | $15.81M derived: sum of 3 quarters · filed 2023-02-10 | -$11.05M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-03-31 | $35.20M 10-Q · filed 2022-05-06 | $35.18M 10-Q · filed 2021-04-30 | $7.71M derived: sum of 2 quarters · filed 2023-02-10 | -$19.15M derived: sum of 3 quarters · filed 2023-02-10 | -$46.66M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2020-12-31 | -$27.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | -$54.35M derived: sum of 2 quarters · filed 2023-02-10 | -$81.86M derived: sum of 3 quarters · filed 2023-02-10 | -$66.50M 10-K · filed 2023-02-10 | |||
| 2020-09-30 | -$26.86M 10-Q · filed 2021-11-03 | -$54.37M derived: sum of 2 quarters · filed 2021-11-03 | -$39.01M 10-Q · filed 2021-11-03 | -$59.90M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-06-30 | -$27.50M 10-Q · filed 2021-07-30 | -$12.15M 10-Q · filed 2021-07-30 | -$33.04M derived: sum of 3 quarters · filed 2022-02-09 | -$10.99M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-03-31 | $15.36M 10-Q · filed 2021-04-30 | -$5.53M derived: sum of 2 quarters · filed 2022-02-09 | $16.52M derived: sum of 3 quarters · filed 2022-02-09 | $7.32M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | -$20.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $1.16M derived: sum of 2 quarters · filed 2022-02-09 | -$8.04M derived: sum of 3 quarters · filed 2022-02-09 | -$2.70M 10-K · filed 2022-02-09 | |||
| 2019-09-30 | $22.05M 10-Q · filed 2020-10-30 | $12.85M derived: sum of 2 quarters · filed 2020-10-30 | $18.19M 10-Q · filed 2020-10-30 | ||||
| 2019-06-30 | -$9.20M 10-Q · filed 2020-07-31 | -$3.86M 10-Q · filed 2020-07-31 | |||||
| 2019-03-31 | $5.34M 10-Q · filed 2020-05-01 | ||||||
| 2011-09-30 | -$238.00K 10-Q · filed 2011-11-03 | $122.00K 10-Q · filed 2011-11-03 | |||||
| 2010-09-30 | -$119.00K 10-Q · filed 2011-11-03 | -$37.00K 10-Q · filed 2011-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |